Xilingyuan Pharmaceutical Co., Ltd. was established in August 2016 with Chengdu kelingyuan Pharmaceutical Technology Co., Ltd. and Guixi PharmaTech Pty Ltd. in Australia. Xilingyuan has the qualification of "national high tech enterprise", and its core technology and management team have been awarded the title of "top innovation and entrepreneurship team" in Sichuan Province and Chengdu City.

The company is committed to building an international leading innovative drug research and development platform, contrast agent drug development platform and catalytic technology platform. The company emphasizes practical innovation and has applied for more than 20 invention patents, many of which have completed the transfer of development rights, bringing considerable economic benefits to the company.